ArticleJournal of surgical oncology2026
Venous Thromboembolism Risk and Prevention After Gastrointestinal Cancer Surgery: Real World Evidence From a Large Integrated Healthcare System.
Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
methodsVenous thromboembolism (VTE) is common and preventable following surgery for gastrointestinal (GI) cancer. In this retrospective cohort study, we aimed to characterize VTE risk factors, prophylaxis, and outcomes among patients who underwent surgery for GI cancer between 2019 and 2021 at Kaiser Permanente Southern California. The discrimination of the Caprini and IMPROVE risk models for predicting VTE was assessed using the area under the receiver operating characteristic curve (AUC).
resultsAmong 2702 patients, the 90-day incidence of perioperative VTE was 2.1%. VTE was associated with older age, prior VTE, thrombophilia, low serum albumin, and blood transfusion, but not procedure time or surgical approach. VTE was especially common among patients with gastric cancer (4.5%). In-hospital prophylaxis was nearly universal, but post-discharge prophylaxis was uncommonly utilized (22.9%). VTE was associated with a five-fold increase in 90-day mortality. Both Caprini (AUC 0.65, 95% CI 0.57-0.72) and IMPROVE (AUC 0.65, 95% CI 0.57-0.73) models demonstrated only fair discrimination.
conclusionsDespite adherence with recommended in-hospital prophylaxis, VTE remains an important complication following GI cancer surgery, carrying with it an increased risk of mortality. DISCUSSION: Suboptimal discrimination of risk prediction models and underutilization of post-discharge prophylaxis represent ongoing opportunities for quality improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.